Aukera is developing first-in-class mTORC1 inhibitors for the treatment of neurological disorders and cancer, focusing on areas of high unmet medical need. The preclinical lead program is a low-nanomolar protein–protein interaction inhibitor with a novel mode of action and an unmatched selectivity profile for mTORC1 over mTORC2. Aukera has developed an AI-powered drug discovery platform that leverages advanced protein design to target previously hard-to-drug proteins.

May 5, 16:00 - 16:15, room Singapore